news
AbbVie’s atogepant illustrates migraine therapy label expansion potential
If approved in Europe, atogepant would provide patients with a new acute treatment option for migraine attacks.
List view / Grid view
atogepant
news
AbbVie gains EU migraine treatment approval
The first once-per-day oral CGRP receptor antagonist gepant treatment has been approved in the EU as a preventative treatment for both chronic and episodic migraines.
news
Oral drug reduces treatment-resistant migraine frequency
Initial data from study results being presented at the 75th American Academy of Neurology Annual Meeting indicate that an oral CGRP inhibitor reduced episodic migraine frequency.
news
AbbVie’s preventative migraine treatment atogepant (Qulipta™) shows promise
AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
news
Atogepant significantly reduces migraines, shows study
A 12-week study revealed that atogepant reduced migraines and headaches and resulted in a 50 percent reduction in mean monthly migraine days.
